KURA · Kura Oncology Inc
United States · RS rating 66 · As of 2026-11-03
| Price | 9.88 USD |
|---|---|
| 1-day change | +0.9% |
| RS rating (overall / 1M / 3M / 12M) | 66 / 41 / 79 / 48 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 24 / 24 / 24 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -8.2% |
| Sales growth Q/Q | -16.4% |
| Distance from 52-week high | +27.3% |
| Market cap (USD) | $822.8M |